H 3 TTA = 4,4′-(((5-((4-(hydroxy-l2-methoxy)phenoxy) methyl)-2,4,6-trimethyl-1,3-phenylene)bis(methylene)) bis(oxy))dibenzoic acid, HFBA = 2-fluorobenzoic acid), were obtained via a one-pot solvothermal reaction of metal salts and organic connectors. The structures of the title two metal-organic coordination compounds were structurally probed via X-ray single crystal diffraction technique. In connection to their structures, the MTT assay was used to access the in vitro antitumor activities for compounds 1 and 2 against the human lung cancer cells (MSTO-211H, NCI-H1299 and NCI-H292).
Introduction
With the rapid industrial development, numerous serious concerns have been raised by people all over the world. Cancer, a most serious concern, has been one of the most notorious diseases globally, leading to millions of deaths every year (Mahale et al., 2018; Nash et al., 2018) . The World Health Organization (WHO) predicts that the incidence of cancer will increase to 21.4 million in the next decade. In this case, the search for new drugs and new treatment techniques has become an important issue related to improving the people's living standard (Siegel et al., 2018) .
Since its discovery, the coordinative chemistry approach has attracted much attention and has been widely used in the design and synthesis of the coordination-based anticancer drugs via the self-assembly approach (Kelland, 2007; Zhang et al., 2018) . For instance, cisplatin is one of the earliest used coordination-based antitumor drugs in the clinical setting, and is still being used in cancer treatment today (Tian et al., 2017) . However, the high toxicity and dose-dependent side effects of the cisplatin restrict its use. The creation of new coordinationbased metal-organic complexes with less side effects in the cancer treatment would be favorable for improving the treatment efficiency (Zarabadi-Poor and Rocha-Rinza, 2018). To date, many new coordination compounds with interesting structural diversity, such as the one-dimensional (1D), two-dimensional (2D), and three-dimensional (3D) infinite frameworks, have been achieved via selfassembly, and the multifarious selection of the building blocks has made the discovery of the new coordinationbased anticancer drugs possible (Chen et al., 2018; Mei et al., 2018; Yang et al., 2018 ). In the current study, two new Zn(II)-Li(I)-based and In(III)-based coordination polymers, namely, {(H 2 NMe 2 )[Zn 3 LiO(BTA) 2 ](DMF) 3 } n (1) and {(Me 2 NH 2 ) 2 [In 2 (TTA) 2 (FBA) 2 ](DMF) 3 } n (2) (Figure 1 ), are obtained successfully and their antitumor activities are also investigated.
Results and discussion

Structural analysis
The structural analysis for 1 by the X ray single-crystal diffraction reveals that the framework of 1 with the chemical formula of {(H 2 NMe 2 )[Zn 3 LiO(BTA) 2 ](DMF) 3 } n is built up from a novel {Zn 3 LiO} secondary building unit (Figure 2A [MO 4 ] coordinating entironment. The Zn-O bond lengths vary from 1.933(5) to 1.980(2) Å, and the Li-O bond lengths range from 1.760(3) to 2.104(7) Å. Three symmetry-related Zn atoms and one Li atom, together with six syn-bridging COO groups on the BTA 3− ligands, form a novel tetrameric {Zn 3 LiO} secondary building unit, which could be regarded as a six-connected building block. In the structure of 1, the BTA 3− linkers are arranged in the crystallographic C 3 -symmetrical axis binding with three different {Zn 3 LiO} units, in which three carboxylate groups adopt a μ 2 -η 1 :η 1 -bridging mode ( Figure 2B ). Each {Zn 3 LiO} unit is connected via six C 3 -symmetric ligands to form a 2D network with a bi-layered structure ( Figure 2C ). The PLATON analysis reveals that complex 1 holds a solvent accessible void of 33.5%, which is occupied by the H 2 NMe 2 cations generated from the decomposition of the DMF solvents. Two such bi-layered structures are further interpenetrated to generate a denser packing framework. When the {Zn 3 LiO} building block could be regarded as a six-bonded node and the BTA 3− linker could be viewed as a 3-bonded node, the topologically simplified framework of 1 can be regarded as a 2D (6,3)-connected binodal net with a (4 3 ) 2 (4 3 · 6 12 ) point symbol ( Figure 2D ). For compound 2, the molecular building unit contains one TTA 3− linker, a FBA − ligand, a crystallographically independent In 3+ cation and one disordered Me 2 NH 2 cation in the molecular building unit. As revealed in Figure 3A, Figure 3B ). The central benzene ring of the TTA 3− is nearly vertical to the other three benzene rings on its arms. Notably, the In(III) clusters are binded by TTA 3− linkers to form a 3D framework structure, in which the honeycomb-liker channels along the a axis could be observed. The cross dimension of the hexagonal-shaped channel is approximately 9.426 Å. The very large solvent-accessible free volume make compound 2 show a two-fold interpenetrated framework with 1D sector-like channel extended in the a axis. The reduced free spaces by the framework interpenetration are occupied by the disordered Me 2 NH 2 cations and the lattice DMF molecules. Interestingly, the F atoms are located on the pore walls of 2, thereby forming the F-decorated channels ( Figure 3C ). To gain a better understanding of the connection pattern of 1, the In(III) cation and the TTA 3− linker can be both considered as two-joint nodes; thus, the entire framework of 2 is topologically simplified into a 3-connected uninodal network with the {10 3 } vertex symbol ( Figure 3D ). The PLATON analysis reveals that complex 2 holds a solvent accessible void of 57.8%. We carried out the powder X-ray diffraction (XRD) measurement for the three compounds, and the results are shown in Figure 4 . The good match between their simulated peaks with the peaks of their prepared samples confirm the phase purity of their prepared samples.
In vitro cytotoxicity study against the tumor cells
In order to preliminary access the anticancer efficacies of the two complexes (1 and 2), their tumor cell growth inhibition activities against human lung cancer cell lines (MSTO-211H, NCI-H1299 and NCI-H292) were evaluated by MTT cell viability assay, with the doxorubicin as the refer drug. Exposure time was set to 48 h and the cell growth inhibition activity effects of cisplatin were used to make a comparison with the results of the title complexes. The DMSO was used to dissolve the compounds at the concentration of 1 μm, and the diluted solution was added into the cell culture.
The data, which represent the means ± SEM values of the three independent tests carried out in duplicate, are plotted in Figure 5 . A descending order could be observed for the anti-proliferative activity of the test complexes toward each type of the tumor cell lines used. This observation can be ascribed to the measured concentration required to inhibit tumor cell proliferation by 50% (IC 50 μ/m). From the results above, we can conclude that the new compounds 1 and 2 demonstrate comparable growth inhibition activities toward all the four types of cancer cells with the reference drug doxorubicin, thus indicating their potential use as antitumor drugs. In addition, the cytotoxicity of the two complexes toward the human epithelial cells (normal cells) and the cell viabilities are shown in Figure 5B . No cytotoxicity was observed when incubating 1 or 2 with the epithelial cells even at the concentration of 100 μg/mL, thus indicating their low cytotoxicity toward the human normal cells.
Conclusion
In summary, two new heterometal-organic frameworks, namely, {(H 2 NMe 2 )[Zn 3 LiO(BTA) 2 ](DMF) 3 } n (1) and {(Me 2 NH 2 ) 2 [In 2 (TTA) 2 (FBA) 2 ](DMF) 3 } n (2), ere obtained via a one-pot solvothermal reaction of metal salts and organic connectors. In connection to their structures, the MTT assay indicates the antitumor activities for compounds 1 and 2 against the human lung cancer cell lines (MSTO-211H, NCI-H1299 and NCI-H292).
Experimental Reagents and general methods
The chemicals used in this work were bought from the commercial companies (Sigma-Aldrich, Tianjin, China) and used as received. The elemental analyzer with the name Perkin-Elmer 2400C (Perkinelmer, North Waltham, MA, USA) was employed to obtain the C, H, N contents of the two coordination compounds. The Cu Kα radiation equipped Bruker D8-ADVANCE (Bruker, Karlsruhe, Germany) was used to collect the powder XRD curves. In a Pyrex tube, Zn(NO 3 ) 2 · 6H 2 O (0.2 mmol, 0.062 g), LiCl (8 mg, 0.2 mmol) and H 3 BTA (35 mg, 0.062 mmol) were added to this vessel subsequently, then DMF (4 mL) was added to the mixture to make a clear solution via stirring. The solution was sealed and then reacted at 120°C for 4 d. After the reaction system returned to room temperature, the light yellow block-shaped crystalline products of 1 were obtained and then washed with DMF-H 2 O. The yield was ca. 13.5 mg (68% based on the H3BTA ligand). Analytical found for C 71 H 65 Li-N 10 O 22 Zn 3 : C, 52.23; H, 4.44; N, 8.29%. Calculate: C, 52.86; H, 4.06; N, 8.68% .
In a 10-mL vial, In(NO 3 ) · 6H 2 O (60 mg, 0.2 mmol), H 3 TTA (0.03 g, 0.053 mmol) and 2-Fluorobenzoic acid (28 mg 0.2 mmol) were mixed in a 3 mL 5:1 (v/v) mixture of DMF/EtOH solution. The solution was placed in an oven at 60°C for 48 h. The yellow crystalline products of 2 were obtained, after which the products were separated by filtration, cleaned with EtOH and air dried (yield: 36% based on H 3 TCM). Analytical found for compound 2 (C 93 H 99 F 2 In 2 N 5 O 25 ): H, 5.49; C, 56.98; N, 3.67. Calculate: H, 5.11; C, 57.15; N, 3 .58%.
X-ray single crystal structure determination
An Oxford Xcalibur E diffractometer (Oxford Instruments, Oxford, UK) with graphite monochromatized Mo Kα radiation (0.71073 Å) was used to collect the reflection data of 1 and 2 at 298 K. The direct method in the XS program was used to obtain the initial structural modes, and the least-squares method in the XL program was used to refine the structural models. All the H atoms were poisoned at their ideal locations and refined using the AFIX commends according to their attached C atoms; then, all non-hydrogen atoms in the two structures were treated anistropically. The respective solvent information of 1 and 2 is obtained from the EA results. Table 1 shows the crystal data and the structure refinement parameter.
Antitumor activity
MSTO-211H, NCI-H1299 and NCI-H292 human lung cancer cell lines were developed in a RPMI 1460 medium supplemented with 10% fetal calf serum, 0.1 g/L streptomycin and 0.1 g/L penicillin. The above systems were incubated in a humidified incubator with air and CO 2 (95:5, V:V) at 37°C. The RPMI 1640 was used to dilute the cell to a concentration of 5 × 10 4 cells/mL. The 96-well cell culture at a volume of 100 μL per cell was used to seed the cells. Then, the system was incubated at 37°C under a humidified CO 2 (5%) surrounding for 1 day. The cells were treated with each complex for 1 day, after which the crystals were removed and the MTT solution (0.5 mg/mL, 150 μL) was added to each well tested and the plates were cultured for 4 h. Afterwards, 100 μL of dimethyl sulfoxide (DMSO) was transferred into each well to dissolve the samples after the MTT-containing media were removed. A microplate reader (PerkinElmer, Waltham, MA, USA) was used to record the absorbance at a wavelength of 450 nm, which was further used in the calculation of the cell relative viability. Each parallel experiment was carried out for at least three times to obtain the mean values. The value for the cell viability was calculated using absorbance peak at 540 nm. 
